Led · Series B · Jan 2026

Founded in 2016 by Drs. Anton Bespalov, Hans Moebius and Rao Vepachedu, Exciva focuses on therapies for neuropsychiatric symptoms in Alzheimer’s disease dementia and related brain disorders. Its lead candidate, Deraphan, combines two CNS-active compounds designed to reduce agitation in Alzheimer’s patients. The company is currently preparing and financing a Phase 2 clinical study to evaluate Deraphan’s therapeutic potential. Exciva leverages proprietary discovery capabilities to identify synergistic compound combinations addressing unmet neuropsychiatric needs. The latest capital infusion strengthens its balance sheet and extends runway through critical mid-stage clinical development. While the company has not disclosed revenue or patient enrollment numbers, the new financing underscores investor confidence in its scientific approach and market opportunity. The refreshed board now includes representatives from key new and existing investors, ensuring broad strategic guidance as the program advances.

Participated · Series B · Jan 2026

Kinaset Therapeutics is focused on creating inhaled, anti-inflammatory medicines for serious respiratory conditions. Its lead candidate, frevecitinib, is a dry-powder, single-capsule pan-JAK inhibitor (JAK1/2/3, TYK2) designed to deliver therapeutic lung concentrations while minimizing systemic exposure. The drug targets both Th2- and Th1-driven disease, giving it potential efficacy across the broad severe asthma population, including patients with non-eosinophilic phenotypes who currently lack effective options. Early clinical data have demonstrated promising safety and pharmacology, and proceeds from the latest financing will fund a Phase 2 dose-ranging study in severe asthma patients. By overcoming historical drug-delivery challenges for inhaled JAK inhibitors, Kinaset aims to provide the first novel, inhaled anti-inflammatory mechanism for asthma in decades. The company operates from Boston and is supported by a syndicate of leading life-science investors.

Participated · Equity · Jan 2025

FIRE1 is a connected medical device solutions company headquartered in Dublin, Ireland, developing the Norm™ heart failure management system. Norm™ enables physician-directed self-management by measuring fluid volume more directly and providing patients with actionable data to manage heart failure. The system is designed to reduce burdens on healthcare staff, keep patients healthier at home, and prevent frequent hospitalizations. FIRE1 completed a $120 million financing to accelerate development and will use the funds to complete a pivotal clinical trial of the Norm™ system. The company has received FDA Breakthrough Device Designation and was accepted into the FDA’s Total Product Lifecycle Advisory Program (TAP). FIRE1 collaborates with researchers, clinicians, patients, and payors and announced board additions tied to the financing. FIRE1 is a connected medical device solutions company developing a remote monitoring solution intended to improve outcomes for people with heart failure. Headquartered in Dublin, Ireland, the company says its mission is to help millions of heart failure patients regain their normal lives. The team works closely with world-leading researchers, clinicians, patients and payors to reduce the burden of chronic disease. FIRE1 recently closed an oversubscribed $25 million financing to accelerate development of its novel home monitoring solution. Management positions the product as a way to reduce hospitalizations and improve care for the large heart-failure population. FIRE1 develops a novel remote monitoring solution aimed at improving outcomes for people with heart failure. The company is led by an experienced medical devices team and works closely with researchers, clinicians, patients and payors. The financing announced will provide capital to further advance its heart-failure remote monitoring product and accelerate development. FIRE1 positions its solution as a means to manage patients at home and reduce hospitalizations and associated costs. The company is headquartered in Dublin and is the 15th medical device company from The Foundry. Management emphasizes collaboration with leading clinicians to support adoption and clinical validation. FIRE1 develops a novel remote monitoring device for medical applications. The Dublin-based company raised $7.5m in a Series B financing. Leadership includes Conor Hanley (President and CEO), John Britton (VP of Commercial Operations), and Fiachra Sweeney (Senior Director of Engineering). In conjunction with the round, The Foundry's Managing Director Mark Deem was appointed Chairman of the Board. FIRE1 is the 15th medical-device company formed by The Foundry, a Menlo Park, California incubator founded in 1998 that creates new medical device companies and works with outside clinicians and inventors. The Foundry has formed over fifteen companies, including Ardian, Concentric Medical, Evalve and Twelve, several of which were later acquired by major medical firms. FIRE1 was launched by The Foundry to develop novel therapeutic devices and is based in Dublin, Ireland. The company plans to use its Series A funding to develop and commercialize solutions addressing certain unmet medical needs. Specific market plans and financing terms were not disclosed in the announcement. The Foundry expanded FIRE1's board to include representatives from investors and partners, and Mark Deem is serving as chief executive. FIRE1 is described as The Foundry's first company created in Ireland and benefits from collaboration with strategic partners in the medical device industry. The announcement frames the partnership as aligning with Covidien's strategy to bring clinically relevant and cost-effective new treatment options to market.

Participated · Series A · Oct 2024

Kivu Bioscience develops next-generation antibody-drug conjugates (ADCs) using a proprietary Synaffix site-specific linker-payload platform and GlycoConnect™ technology. The platform couples linkers to asparagine-297 to produce highly homogeneous, stable ADCs that the company says reduce off-target toxicity and widen the therapeutic window. Kivu's assets are in late-stage preclinical studies, including a Topo1i-based ADC pipeline targeting solid tumors. The company plans to advance its first two lead candidates into Phase 1 trials in 2025 and to move multiple oncology programs into the clinic. Kivu is led by an experienced team headed by Mohit Trikha, Ph.D., and is headquartered in San Francisco, CA. The company closed a $92 million Series A to support clinical development across its ADC programs.

Led · Series C · Sep 2024

ImmunOs Therapeutics leverages an HLA-based technology platform to develop first-in-class therapeutics targeting cancer and autoimmune diseases. Its lead program, IOS-1002, is a multi-functional HLA-fusion protein that binds specific LILRB and KIR receptors to stimulate both the innate and adaptive immune systems. The company is developing IOS-1002 as a cancer therapeutic intended to eliminate tumor cells and is also exploring different modalities to agonize receptors for autoimmune disease modulation. ImmunOs is advancing IOS-1002 through a Phase Ia dose-escalation clinical trial as a monotherapy and in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). The company is led by Executive Chairman Reinhard Ambros and is based in Schlieren, Switzerland. ImmunOs Therapeutics AG leverages an HLA-based technology platform to develop first-in-class therapeutics for cancer and autoimmune diseases. Its lead program, IOS-1002 (formerly iosH2), is a multi-functional fusion protein based on a naturally occurring HLA that targets LILRB1, LILRB2 and KIR3DL1 and synergizes with the adaptive immune system to drive anti-tumor activity. A Phase 1 clinical trial for IOS-1002 is planned to start in the second half of 2022, and the company intends to progress the program through Phase 2. ImmunOs is also developing antibodies to block activation of specific HLA proteins associated with autoimmune diseases and is advancing additional oncology and autoimmune programs toward clinical development. The company has established a U.S. subsidiary to expand its international reach, execute future U.S. clinical trials, and strengthen transatlantic operations and team. ImmunOs Therapeutics AG is a Swiss biotechnology company developing a new class of HLA-based biologic therapeutics for cancer and autoimmune diseases. Its proprietary R&D platform creates HLA-based therapeutics that address multiple targets via a single fusion protein; the company's lead program is a multifunctional fusion protein that blocks specific LILRB receptors to activate anti-tumor responses. ImmunOs is also developing a novel HLA‑open conformer‑specific monoclonal antibody, OCi, intended to treat immune-mediated inflammatory diseases and to act upstream of current therapies. The company plans in vivo proof-of-concept studies in spondyloarthritis and intends to extend OCi development to psoriasis and inflammatory bowel disease following successful results. Research is being conducted through an international consortium with ProteoGenix SAS (optimizing phage display for HLA mAb development) and Amsterdam UMC (providing animal models and clinical expertise). ImmunOs has received public funding from the EU’s Eurostars-2 programme and the Swiss Innovation Agency Innosuisse and is supported by investors including Pfizer Ventures, BioMed Partners and Redalpine. ImmunOs Therapeutics AG develops novel human immunomodulatory proteins that act on the innate immune system to activate anti-tumor responses. Its lead program is the iosH platform, with lead agent iosH2 being advanced as a potential treatment for both solid and liquid tumors. The company’s approach builds on research into HLA open conformer modulation of immune cells and targets diverse immunoregulatory receptors to modulate the tumor microenvironment. ImmunOs plans to complete first-in-human trials of iosH2 and to broaden the iosH platform by advancing additional preclinical programs in cancer and auto-immunity. The company is a spin-off of the University of Zurich and the University of Basel. Leadership includes CEO Sean R. Smith and CSO and co-founder Dr. Osiris Marroquin Belaunzaran, and the company states its mission is to develop novel therapeutics to improve the lives of patients with serious disease. ImmunOs Therapeutics AG is a Swiss biotechnology spin-off of the University of Zurich and University of Basel developing a next-generation platform of multitasking human immunomodulatory proteins for cancer. Its lead clinical candidate is a single multitasking protein agent aimed at treating solid tumors. The platform targets diverse immunoregulatory receptors to activate anti-tumor responses, working directly on the innate immune system (MDSCs, macrophages, NK cells and neutrophils) and indirectly on the adaptive system by enabling T cell expansion. ImmunOs positions its proteins for use both as monotherapy and in combination with checkpoint inhibitors (PD-1, CTLA-4, PD-L1) and costimulatory agonists (e.g., 4-1BB). The team brings experience in drug development and global commercialization in immunotherapy, immunology, and oncology. Proceeds from the announced financing will be used to advance the lead clinical candidate.